ARRIVENT BIOPHARMA INC
AVBPNASDAQTrading Snapshot
- Day Range
- $29.34 – $29.74
- 52-Week Range
- $17.00 – $35.83
- Volume
- $3.30B
- Avg Volume
- $2.87B
- Shares Outstanding
- 46.6M
- Next Earnings
- Dec 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $87M
- Last Q Revenue
- $20M
- P/E Ratio
- -8.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.44
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +14.5%
Why Investors Own AVBP
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ARRIVENT BIOPHARMA INC
AVBP
StockOtter · stockotter.spaceAbout ARRIVENT BIOPHARMA INC
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts
ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst ha
Deutsche Bank AG Acquires Shares of 39,180 ArriVent BioPharma, Inc. $AVBP
Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 39,180 shares
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case
The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration acros
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One equ
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP
Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) by 758.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceuti